NSCLC Videos

Videos

Combining LCT and Brigatinib May Benefit Patients With ALK+ NSCLC

05/27/2020

David Carbone, MD, PhD, comments on a study evaluating the use of LCT plus brigatinib for patients with ALK-positive NSCLC.

David Carbone, MD, PhD, comments...

05/27/2020

Oncology

Videos

Ongoing Trial Will Assess Trastuzumab Deruxtecan–Pembrolizumab Combo for Breast Cancer, NSCLC

05/27/2020

Hope Rugo, MD, looks forward to the safety and efficacy findings of an ongoing study examining trastuzumab deruxtecan plus pembrolizumab for breast cancer and NSCLC.

Hope Rugo, MD, looks forward to...

05/27/2020

Oncology

Videos

Pembrolizumab Added to Chemo Maintains OS, PFS Benefits in Metastatic NSCLC

05/27/2020

Yasir Elamin, MD, discusses the clinical significance of the KEYNOTE-189 clinical trial evaluating the use of chemo plus pembrolizumab for metastatic, nonsquamous NSCLC.

Yasir Elamin, MD, discusses the...

05/27/2020

Oncology

Videos

The Role of Antiangiogenics in NSCLC

05/14/2020

Helen Ross, MD, discusses the role of antiangiogenics over time in treating NSCLC.

Helen Ross, MD, discusses the...

05/14/2020

Oncology

Videos

Treatment of ALK-Positive and ROS1 Rearrangements in NSCLC

05/07/2020

Helen Ross, MD, Director of Thoracic Malignancies Program, Mayo Clinic, Scottsdale, Arizona, discusses the role of ALK-Positive and ROS1 rearrangements in patients with NSCLC and treatment options.

Helen Ross, MD, Director of...

05/07/2020

Oncology

Videos

Managing Oncogenic Driver Mutations in NSCLC

04/16/2020

Helen Ross, MD, discusses the need to screen patients with NSCLC for driver mutations via NGS at diagnosis and after progression to help select first-, second-, and third-line targeted therapies.

Helen Ross, MD, discusses the...

04/16/2020

Oncology

Videos

Lyudmila Bazhenova, MD, Talks About Immune-Related AEs in Lung Cancer

03/25/2020

Dr Bazhenova talks about the management of immune-related adverse events in patients with lung cancer.

Dr Bazhenova talks about the...

03/25/2020

Oncology

Videos

Remarkable Breakthroughs in the Treatment of Advanced NSCLC

03/22/2020

Martin J. Edelman, MD, discusses how the treatment landscape for advanced NSCLC has evolved in recent years.

Martin J. Edelman, MD, discusses...

03/22/2020

Oncology

Videos

The Future of Lung Cancer Screening

03/03/2020

James L. Mulshine, MD, talks about what the future holds vis-a-vis advancements in lung cancer screening.

James L. Mulshine, MD, talks...

03/03/2020

Oncology

Videos

Fadi Braiteh, MD, Discusses the Ins and Outs of Entrectinib Therapy for NSCLC

12/03/2019

Dr Braiteh spoke in detail about the use of entrectinib therapy in patients with NSCLC at the 2019 Perspectives in Thoracic Oncology meeting.

Dr Braiteh spoke in detail about...

12/03/2019

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology